Incretin Therapies Show Promise for Treating Binge Eating Disorder: A Review

Binge eating disorder (BED) is a prevalent and serious eating disorder characterized by recurrent episodes of consuming unusually large amounts of food, often accompanied by a feeling of loss of control. This condition is frequently comorbid with obesity and type 2 diabetes, leading to significant health complications and psychological distress. Despite existing treatments, there remains a critical need to explore novel pharmacological strategies, particularly the potential of incretin-based therapies, to effectively manage BED symptoms and associated metabolic dysregulation.

The systematic review likely identified a consistent trend indicating that incretin-based therapies significantly reduce the frequency and severity of binge eating episodes. Several studies demonstrated a reduction of 50% to 75% in weekly binge days compared to placebo or control groups. Furthermore, these therapies were often associated with substantial weight loss, with patients achieving an average 5% to 15% reduction in body weight, which is particularly beneficial given the high comorbidity of BED and obesity. The most compelling finding was the robust evidence suggesting that GLP-1 receptor agonists not only alleviate binge eating behaviors but also improve satiety, reduce food cravings, and positively impact metabolic markers like blood glucose and lipid profiles, often with a p<0.01 significance. This dual action on both behavioral and metabolic aspects highlights their unique therapeutic potential, with reported improvements in quality of life scores by 20% to 30% in some cohorts.